Top Canadian Cannabis Stocks to Watch in November 2025

Canadian cannabis stocks Tilray Brands (TLRY), Cronos Group (CRON), and Aurora Cannabis (ACB) are highlighted for their strategic positioning and financial improvements in late 2025, signaling potential renewed growth amidst an evolving market. Tilray is expanding its U.S. presence and improving cannabis gross margins to 40% despite impairment charges, while Cronos Group achieved over 30% revenue growth in 2024 and positive net income in early 2025, underpinned by a strong balance sheet. Aurora Cannabis, focusing on global medical exports, reported over 35% total revenue growth in 2025, with medical sales up over 50%, reflecting a successful pivot to higher-margin segments and improved profitability.

Analysis

The Canadian cannabis market is undergoing a strategic shift towards profitability, cost reduction, and high-margin opportunities like medical exports and branded products, amidst evolving global demand and potential U.S. legalization. Three key players, Tilray Brands (TLRY), Cronos Group (CRON), and Aurora Cannabis (ACB), are highlighted for their distinct approaches to capitalize on these trends in November 2025. This sector-wide pivot aims to enhance financial resilience despite regulatory and pricing challenges.

Tilray Brands reported a 4% year-over-year total net revenue increase to over $820 million in fiscal 2025, with cannabis gross margins expanding from 33% to 40%, despite a net loss from impairment charges. Cronos Group demonstrated robust financial improvement, with 2024 annual net revenue rising over 30% and achieving positive net income in early 2025, supported by a strong balance sheet. Aurora Cannabis saw a 35% year-over-year total revenue climb in 2025, driven by a 50% increase in high-margin medical cannabis sales, reflecting a successful strategic pivot.

These companies are strategically positioning themselves for future growth, with Tilray focusing on U.S. hemp-derived products and operational streamlining, Cronos emphasizing innovation and cannabinoid research for global markets, and Aurora leveraging its international medical cannabis expertise. Their collective efforts in cost management, product diversification, and international expansion are designed to improve profitability and stabilize cash flows, preparing them for potential broader legalization and market maturation. The overall sentiment for these stocks is strongly positive, indicating renewed investor confidence.

Key Decisions for Investors

• Monitor regulatory developments in the U.S. for potential federal legalization, which could significantly impact the U.S. market entry strategies of these Canadian firms.
• Evaluate each company's specific profitability drivers, such as Tilray's improved gross margins, Cronos's positive net income, and Aurora's medical cannabis sales growth, for sustained financial health.
• Assess the strategic positioning of each player—Tilray's U.S. consumer focus, Cronos's R&D, and Aurora's global medical exports—to determine alignment with long-term market trends and competitive advantages.
• Maintain strict risk management protocols and utilize technical analysis to navigate the inherent volatility of the cannabis sector, identifying opportune entry points.